Activation of AKT has been associated with poor prognosis and chemotherapy resistance in B-ALL, and AKT overexpression in the human B-ALL cell line NALM6 reduces sensitivity to numerous chemotherapeutic agents in vitro [61]. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.